Side effects of leukotriene receptor antagonists in asthmatic children

Iranian Journal of Pediatrics

Volumn 25, Issue 5, 2015, Pages

  Erdem, Semiha Bahceci ^a   Nacaroglu, Hikmet Tekin ^a   Karkiner, Canan Sule Unsal ^a   Gunay, Ilker ^a   Can, Demet ^a  

^a Behcet Uz Children's Hospital   (Turkey)

Author keywords

Asthma; Children; Leukotriene receptor antagonists; Side effect; Wheezing

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; AGE; AGITATION; APHTHOUS STOMATITIS; ARTICLE; ASTHMA; CHILD; CONVULSION; DEPRESSION; DRUG SAFETY; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPERACTIVITY; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; NYCTOPHOBIA; PHOBIA; PRESCHOOL CHILD; RASH; RETROSPECTIVE STUDY; SEX DIFFERENCE; SLEEP DISORDER; SOMNOLENCE; TREATMENT WITHDRAWAL; WHEEZING;

EID: 84944929686     PISSN: 20082142     EISSN: 20082150     Source Type: Journal    
DOI: 10.5812/ijp.3313     Document Type: Article

References (33)

1. Kocyigit A, Gulcan Oksuz B, Yarar F, Uzun F, Igde M, Islek I. Hallucination development with montelukast in a child with asthma: case presentation. Iran J Allergy Asthma Immunol. 2013;12(4):397-9.
2. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulm- onol. 2009;44(6):568-79.
3. Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-Induced Adverse Drug Reactions: A Review of Case Re- ports in the Literature. Pharmacology. 2014;94(1-2):60-70.
4. Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA) 2014 (revised), available from: http://www.ginasthma.org.
5. ERS task force. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J. 2008;32(4):1096-1110.
6. Drazen JM. Leukotriens, Asthma and Rinitis. United States: Blackwell Scientific Publications; 1995. pp. 838-50.
7. O’Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997;111(suppl):27-34.
8. Peters-Golden M. Gleason MM. Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006;36(6):689-703.
9. Nelson H, Kemp J, Berger W, Corren J, Casale T, Dube L, et al. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Ann Allergy Asthma Immunol. 2007;99(2):178-84.
10. Kraft M, Cairns CB, Ellison MC, Pak J, Irvin C, Wenzel S. Imrovements in distal lung function correlate with asthma symptoms af- ter treatment with oral montelukast. Chest. 2006;130(6):1726-1732.
11. Mandeep W, Rakesh L, Kabra SK. Montelukast in Pediatric Asthma Management. Indian J Pediatr. 2006;73(4):275-82.
12. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-con- troller therapy. N Engl J Med. 2011;364(18):1695-707.
13. Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclo- methasone. Eur Respir J. 2003;21(1):123-8.
14. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised dou- ble-blind placebo-controlled trial. Lancet. 2001;357(9273):2007-11.
15. Wahn U, Dass SB. Rewiev of recentresults of montelukastuse as a monotherapy in children with mild asthma. Clin Ther. 2008;30:1026-35.
16. Montella S, Maglione M, De Stefano S, Manna A, Di Giorgio A, Santamaria F. Update on leukotriene receptor antagonists in preschool children wheezing disorders. Ital J Pediatr. 2012;38:29.
17. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171(4):315-22.
18. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma con- troller agents. Eur Respir J. 2006;27(3):495-503.
19. Silva NL, Damayanthi H, Rajapakse AC, Rodrigo C, Rajapakse S. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10(1):24.
20. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/ or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;16:5.CD002314.
21. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32(7):1020–8.
22. Wechsler ME, Pauwels R, Drazen JM. Leucotriene modifiers and Churg-Strauss syndrome: advers effect or response to corticosteroid with drawal? Drug Saf. 1999;21(4):241-251.
23. Xie JX, Wei JF, Meng L. Montelukast sodiuminduced hematuria: a case report and literature review of 19 cases in mainland China. Int J Clin Pharmacol Ther. 2013;51(12):958–962.
24. Cuchacovich R, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol. 2007;26(10):1769–71.
25. Palodhi S, Ray Chaudhuri P, Biswas A, Bera T. Montelukast induced hypertriglyceridemia. Indian Med Gaz. 2012;146:334–336.
26. Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK. A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis. J Young Pharm. 2013;5(2):64–66.
27. Ding Q, Fang SH, Zhou Y, Zhang LH, Zhang WP, Chen Z, et al. Cysteinyl leukotriene receptor 1 partially mediates brain cryoinjury in mice. Acta Pharmacol Sin. 2007;28(7):945–952.
28. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):699-706.
29. Dube LM, Swanson LJ, Awni W. Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma: clinical pharmacokinetics and safety. Clin Rev Allergy Immunol. 1999;17(1-2):213-221.
30. Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009;18(9):858–64.
31. Zhou EH, Kaplan S, Mosholder A, Moeny D, Ding Y, Wu Y, et al. Antidepressant medication dispensing among montelukast initiators. J Asthma. 2013;50(9):990–5.
32. Celmeli F, Celmeli G, Surer Adanır A, Türkkahraman D. Suicide Behaviour After Montelukast Usage: A Case Report. Turkish Journal of Pediatric Disease. 2014;4(8):212-214.
33. Bygdell M, Brunlöf G, Wallerstedt SM, Kindblom JM. Psychiatric advers drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmaco epidemiol Drug Saf. 2012;21(1):79-86.